1. Home
  2. BK vs VRTX Comparison

BK vs VRTX Comparison

Compare BK & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Bank of New York Mellon Corporation

BK

The Bank of New York Mellon Corporation

HOLD

Current Price

$116.40

Market Cap

75.3B

Sector

Finance

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$462.76

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BK
VRTX
Founded
1784
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
EDP Services
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
75.3B
115.7B
IPO Year
2012
2006

Fundamental Metrics

Financial Performance
Metric
BK
VRTX
Price
$116.40
$462.76
Analyst Decision
Buy
Buy
Analyst Count
12
28
Target Price
$128.75
$537.64
AVG Volume (30 Days)
2.7M
1.1M
Earning Date
04-14-2026
05-15-2026
Dividend Yield
1.82%
N/A
EPS Growth
27.59
836.54
EPS
7.40
15.32
Revenue
$20,080,000,000.00
$2,488,652,000.00
Revenue This Year
$9.01
$10.79
Revenue Next Year
$4.61
$10.14
P/E Ratio
$15.74
$30.25
Revenue Growth
7.85
46.20
52 Week Low
$70.46
$362.50
52 Week High
$128.76
$515.67

Technical Indicators

Market Signals
Indicator
BK
VRTX
Relative Strength Index (RSI) 46.19 45.07
Support Level $113.57 $443.06
Resistance Level $118.92 $473.78
Average True Range (ATR) 2.93 16.29
MACD -0.12 -2.52
Stochastic Oscillator 41.62 20.38

Price Performance

Historical Comparison
BK
VRTX

About BK The Bank of New York Mellon Corporation

Bank of New York Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors, delivering investment management and services in 35 countries and more than 100 markets. BNY is the largest global custody bank in the world, with $52.1 trillion in under custody or administration (as of December 2024), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY's asset-management division manages about $2.0 trillion in assets.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: